AnalystsAndy HsiehAndy Hsieh's Stock Forecasts
AnalystsAndy Hsieh
Sectors:
Analyst Ranking
Top 21%
#1153 out of 5511 analysts
Average Return
+53.22%
Win Rate
60%9 out of 15
Risk vs Reward
Poor
Good
Andy Hsieh's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +277.41% | $14.03 | $52.95 | 2025-11-03 - 2026-05-04 | Buy |
Cymabay Therapeutics IncCBAY | +276.73% | $8.55 | $32.21 | 2023-04-05 - 2024-02-12 | Buy |
Rayzebio IncRYZB | +198.20% | $20.59 | $61.40 | 2023-10-06 - 2023-12-26 | Buy |
Structure Therapeutics IncGPCR | +165.18% | $23.75 | $62.98 | 2025-02-28 - 2026-02-27 | Buy |
Fusion Pharmaceuticals IncFUSN | +78.91% | $2.56 | $4.58 | 2022-07-06 - 2023-07-05 | Buy |
Andy Hsieh Analyst Color
Get additional color on Andy Hsieh's coverage of popular stocks
Andy Hsieh's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Enliven Therapeutics IncELVN | 1 | Buy | N/A | N/A | Initiates Coverage On | a month ago |
Cardiff Oncology IncCRDF | 1 | Hold | N/A | N/A | Downgrades | a month ago |
Lantheus Holdings IncLNTH | 2 | Hold | N/A | N/A | Downgrades | a month ago |
Aardvark Therapeutics IncAARD | 1 | Buy | N/A | N/A | Initiates Coverage On | 9 months ago |
Terns Pharmaceuticals IncTERN | 2 | Buy | N/A | N/A | Upgrades | 10 months ago |
Elevation Oncology IncELEV | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Corbus Pharmaceuticals Holdings IncCRBP | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Skye Bioscience IncSKYE | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Altimmune IncALT | 1 | Hold | N/A | N/A | Initiates Coverage On | 2 years ago |
Structure Therapeutics IncGPCR | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Bioage Labs IncBIOA | 1 | Hold | N/A | N/A | Initiates Coverage On | 2 years ago |
Mersana Therapeutics IncMRSN | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Pyxis Oncology IncPYXS | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Fusion Pharmaceuticals IncFUSN | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Cymabay Therapeutics IncCBAY | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Rayzebio IncRYZB | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Aravive IncARAV | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Actinium Pharmaceuticals IncATNM | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Point Biopharma Global IncPNT | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Icosavax IncICVX | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Barinthus Biotherapeutics PLCBRNS | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.